

Timeline



Enantis

2019

Enantis will be on the look for bringing FGF7-STAB® and FGF10-STAB® to the market. These products will further boost the growth of the company over the upcoming years.

2018

Enantis successfully negotiated the first distribution agreement of its history. In October 2018, Enantis signed a distribution contract with major player in the cell culture market and FGF2-STAB® was launched globally.

2017

Enantis is on the look for a strong investor who will help the company commercialize its products and help with the further growth.

2016

Enantis is successful in receiving three H2020 EU grants including the highly prestigious SME Instrument phase 2. On February, 2017, Enantis signs distribution contracts with BioVendor and launches stabilized FGF2 (FGF2-STAB®) on the cell culture market.

2015

Enantis conducts feasibility analysis for stabilized fibroblast growth factors funded by SME Instrument, phase 1 (H2020 of the European Commission under Grant Agreement 673225) and receives the Werner von Siemens Excellence Award in the most important result of the development / innovation category

2014

Enantis enters the field of fibroblast growth factors, and in the same year, Enantis, Loschmidt Laboratories, and the Photon Systems Instrument receive an award for The Best Cooperation of the Year.

2013

Stabilizing proteins via protein engineering becomes a central concern for Enantis. The company's state-of-the-art protein engineering platform begins to take shape.

2012

Enantis is involved in the NewProt project (FP7 of the European Commission under Grant Agreement 318338). The concept of the NewProt project is to combine and integrate the best European software into a homogeneous portal for in silico protein engineering.

2011

Enantis and the Photon Systems Instrument start cooperation on the development of a biosensor for detection of halogenated hydrocarbons.

2008

Enantis moves from academic laboratories to its own labs in the biotechnology incubator JIC INBIT and becomes an independent company.

2007

The technology platform of Enantis is based on haloalkane dehalogenases enzymes and encompasses the synthesis of optically pure compounds by biocatalysis and biodegradation of environmental pollutants and warfare chemicals.

2006

Enantis is established on February 28, 2006, as a spin-off company from Masaryk University.